These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 19152222)

  • 1. Cardiomyocytes derived from human embryonic stem cells - characteristics and utility for drug discovery.
    Steel D; Hyllner J; Sartipy P
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):133-40. PubMed ID: 19152222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The application of human embryonic stem cell technologies to drug discovery.
    Sartipy P; Björquist P; Strehl R; Hyllner J
    Drug Discov Today; 2007 Sep; 12(17-18):688-99. PubMed ID: 17826681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery.
    Braam SR; Passier R; Mummery CL
    Trends Pharmacol Sci; 2009 Oct; 30(10):536-45. PubMed ID: 19762090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Embryonic stem cells in pharmacology].
    Laustriat D; Gide J; Héchard C; Peschanski M
    Med Sci (Paris); 2009 May; 25 Spec No 2():32-8. PubMed ID: 19848191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of cardiomyocytes from new human embryonic stem cell lines derived from poor-quality blastocysts.
    Raya A; Rodríguez-Pizà I; Arán B; Consiglio A; Barri PN; Veiga A; Izpisúa Belmonte JC
    Cold Spring Harb Symp Quant Biol; 2008; 73():127-35. PubMed ID: 19028986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human embryonic stem cells for cardiomyogenesis.
    Habib M; Caspi O; Gepstein L
    J Mol Cell Cardiol; 2008 Oct; 45(4):462-74. PubMed ID: 18775434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of human embryonic stem cell-derived mesoderm and cardiac cells using size-specified aggregates in an oxygen-controlled bioreactor.
    Niebruegge S; Bauwens CL; Peerani R; Thavandiran N; Masse S; Sevaptisidis E; Nanthakumar K; Woodhouse K; Husain M; Kumacheva E; Zandstra PW
    Biotechnol Bioeng; 2009 Feb; 102(2):493-507. PubMed ID: 18767184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human embryonic stem cells: current technologies and emerging industrial applications.
    Améen C; Strehl R; Björquist P; Lindahl A; Hyllner J; Sartipy P
    Crit Rev Oncol Hematol; 2008 Jan; 65(1):54-80. PubMed ID: 17689256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiomyocytes derived from human pluripotent stem cells for drug screening.
    Zeevi-Levin N; Itskovitz-Eldor J; Binah O
    Pharmacol Ther; 2012 May; 134(2):180-8. PubMed ID: 22269465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells.
    Yokoo N; Baba S; Kaichi S; Niwa A; Mima T; Doi H; Yamanaka S; Nakahata T; Heike T
    Biochem Biophys Res Commun; 2009 Sep; 387(3):482-8. PubMed ID: 19615974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Embryonic stem cells as a novel cell source of cell-based biosensors.
    Liu Q; Huang H; Cai H; Xu Y; Li Y; Li R; Wang P
    Biosens Bioelectron; 2007 Jan; 22(6):810-5. PubMed ID: 16621504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects for pluripotent stem cell-derived cardiomyocytes in cardiac cell therapy and as disease models.
    Freund C; Mummery CL
    J Cell Biochem; 2009 Jul; 107(4):592-9. PubMed ID: 19449339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical assessment of cardiac toxicity.
    Kettenhofen R; Bohlen H
    Drug Discov Today; 2008 Aug; 13(15-16):702-7. PubMed ID: 18602016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developmental changes in cardiomyocytes differentiated from human embryonic stem cells: a molecular and electrophysiological approach.
    Sartiani L; Bettiol E; Stillitano F; Mugelli A; Cerbai E; Jaconi ME
    Stem Cells; 2007 May; 25(5):1136-44. PubMed ID: 17255522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiomyocytes.
    Yang X; Guo XM; Wang CY; Tian XC
    Methods Enzymol; 2006; 418():267-83. PubMed ID: 17141041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of pluripotency: from avian, rodents, to primates.
    Martins-Taylor K; Xu RH
    J Cell Biochem; 2010 Jan; 109(1):16-25. PubMed ID: 19937733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiomyocyte differentiation of human induced pluripotent stem cells.
    Zwi L; Caspi O; Arbel G; Huber I; Gepstein A; Park IH; Gepstein L
    Circulation; 2009 Oct; 120(15):1513-23. PubMed ID: 19786631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiomyocyte differentiation of pluripotent stem cells and their use as cardiac disease models.
    Dambrot C; Passier R; Atsma D; Mummery CL
    Biochem J; 2011 Feb; 434(1):25-35. PubMed ID: 21269276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stem cells for drug screening.
    Laposa RR
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):240-5. PubMed ID: 21499120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impacts of recent advances in cardiovascular regenerative medicine on clinical therapies and drug discovery.
    Murata M; Tohyama S; Fukuda K
    Pharmacol Ther; 2010 May; 126(2):109-18. PubMed ID: 20156482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.